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Background
Recent reports indicate that epigallocatechin-3-gallate
(EGCG), the most abundant catechin in green tea, is
potent to inhibit fibril formation of several amyloido-
genic proteins in vitro. In vivo studies revealed reduc-
tion of left ventricular myocardial mass (LVM) after 12
months of daily consumption of 450 mg EGCG. How-
ever, the underlying process of LVM reduction, either
due to reduction of amyloid or due to atrophy of cardio-
myocytes, remained unknown. T1-mapping has the
potential to monitor the extent of the extracellular
volume (ECV). We sought to investigate the use of T1
mapping for monitoring of treatment effects in a cohort
of patients with senile systemic amyloidosis (SSA) trea-
ted with EGCG for 12 months.
Methods
CMR examinations were performed in 8 patients (70 ±
8 years, 7 males) with histologically proven SSA before
and 12 months after daily consumption of 450 mg
EGCG using a 1.5 T CMR scanner (Achieva, Philips
Healthcare). Short axis slices were acquired using SSFP-
sequences to measure left ventricular volumes, ejection
fraction (EF) and LVM. T1-maps were created out of 11
mid-ventricular short axis views with increasing inver-
sion times (TI; 100-4400 msec) using a single breath-
hold modified Look-Locker inversion-recovery sequence
(MOLLI, TR/TE = 3,5/1,8 msec, flip angle = 35°) in late
diastole before and 15 minutes after injection of gadoli-
nium-DTPA contrast agent (0.2 mmol/kg body weight).
ECV was calculated using the formula given in Figure 1.
Results
After 12 months of EGCG consumption a significant
decrease of LVM (-14.5 ± 12.9 g, p < 0.05, Figure 2) was
observed. Moreover, a significant decrease of native T1
(-63.3 ± 64.1 ms, p < 0.05, Figure 2) was noticed. There
was no significant change in ECV and EF.
Conclusions
This is a preliminary study to evaluate T1-mapping
for the monitoring of treatment effects in patients
with SSA. The decrease of T1 relaxation time after 12
months of EGCG treatment might possibly indicate a
reduction of amyloid load. Thus, T1-mapping might be
a potential tool for monitoring further experimental
therapies. However, the considerable gap between native
T1 and ECV measurements remain unexplained and
needs to be investigated in a future study.
Funding
None.
Department of Cardiology, University of Heidelberg, Heidelberg, Germany
Figure 1 T1 myo pre: native T1 relaxation time for myocardium
T1 myo post: post-contrast T1 relaxation time for myocardium
T1 blood pre: native T1 relaxation time for blood T1 blood
post: post-contrast T1 relaxation time for blood.
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